What is the recommended approach to assess and manage a patient with interstitial lung disease?

Assessment and Management of Interstitial Lung Disease

Initial Diagnostic Evaluation

All patients with suspected ILD require high-resolution CT (HRCT) as the gold standard imaging test, achieving 95.7% sensitivity for disease involving ≥20% of lung parenchyma, even in asymptomatic patients. 1

Clinical Assessment

• Evaluate for fine, dry "Velcro-type" end-inspiratory crackles, which are present in >80% of idiopathic pulmonary fibrosis patients and are the hallmark auscultatory finding 1
• Assess for dyspnea on exertion, though up to 90% of patients with early connective tissue disease-associated ILD may be asymptomatic 1, 2
• Document chronic non-productive cough, present in approximately 30% of ILD patients 3
• Examine for digital clubbing (present in 25-50% of IPF cases), cyanosis in advanced disease, and signs of right heart failure including peripheral edema and right ventricular heave 1

Exposure and Etiologic Assessment

• Obtain comprehensive environmental and occupational exposure history (mold, air pollution, occupational vapors, gases, dusts, fumes), as these factors interact with genetic susceptibility to drive ILD development 1
• Document detailed medication history to identify drug-induced ILD 4
• Assess for family history of pulmonary fibrosis, as 15-30% of first-degree relatives of patients with familial pulmonary fibrosis have interstitial lung abnormalities on CT 5, 1
• Evaluate for connective tissue disease manifestations, as CTD-associated ILD accounts for 25% of all ILD cases 3

Laboratory Evaluation

• Obtain complete blood count with differential, C-reactive protein, serum creatinine, and liver function tests 1
• Test autoimmune serologies including anti-nuclear antibodies, anti-citrullinated cyclic peptide antibodies, rheumatoid factor, anti-topoisomerase (Scl-70), and anti-neutrophilic cytoplasmic antibody (MPO-ANCA) 1, 2
• Routine measurement of serum biomarkers (MMP-7, surfactant protein D, CCL-18, KL-6) is not recommended for differentiating IPF from other ILDs 1

HRCT Imaging Protocol

• HRCT acquisition must include inspiratory prone and supine end-expiratory images with slice thickness ≤2 mm 1
• Identify specific patterns:
  • Usual interstitial pneumonia (UIP): subpleural reticulation, traction bronchiectasis, honeycombing (mandatory for definite UIP), basal-peripheral distribution 1
  • Non-specific interstitial pneumonia (NSIP): ground-glass opacities with reticulation and more uniform distribution 1
  • Prominent diffuse ground-glass attenuation or mosaic-pattern ground-glass argues against UIP 1

Pulmonary Function Testing

• Perform spirometry to measure forced vital capacity (FVC), which identifies restrictive pattern 1, 2
• Measure total lung capacity (TLC) to confirm restrictive physiology 1
• Assess diffusion capacity for carbon monoxide (DLCO), which is the most sensitive functional parameter for early ILD detection 1, 2
• Conduct 6-minute walk test with oxygen saturation monitoring to detect exercise-induced desaturation indicating gas exchange impairment 1, 2

Cardiovascular Evaluation

• Perform routine echocardiography in the initial work-up to identify pulmonary hypertension, which is associated with worse prognosis and develops in up to 85% of patients with end-stage fibrotic ILD 1, 3

Tissue Diagnosis Strategy

When HRCT demonstrates a definite UIP pattern in the appropriate clinical context, surgical lung biopsy, transbronchial biopsy, or cryobiopsy is not indicated. 1

Biopsy Indications and Technique

• When HRCT and clinical assessment do not yield a definitive diagnosis, transbronchial lung cryobiopsy (TBLC) is suggested as the first-line biopsy method 1
• TBLC provides larger specimens with fewer crush artifacts and has a lower complication rate (17.2% unclassifiable cases) compared to surgical lung biopsy (1.3% unclassifiable cases) 1
• Surgical lung biopsy via video-assisted thoracoscopic surgery (VATS) should be reserved for rapidly progressive ILD or when TBLC results are nondiagnostic 1

Bronchoalveolar Lavage (BAL) Criteria

• BAL cellular analysis is not recommended in patients with a UIP pattern on HRCT 1
• When performed, interpret BAL findings as follows:
  • Lymphocyte count >25% suggests granulomatous diseases (sarcoidosis, hypersensitivity pneumonitis), cellular NSIP, drug-induced lung injury, or cryptogenic organizing pneumonia 1
  • Lymphocyte count >50% strongly points toward hypersensitivity pneumonitis or cellular NSIP 1
  • Eosinophil count >25% is virtually diagnostic of acute or chronic eosinophilic pneumonia 1
  • CD4+/CD8- ratio >4 is highly specific for sarcoidosis 1

Multidisciplinary Discussion

A formal multidisciplinary discussion involving pulmonologists, radiologists, and pathologists experienced in ILD is mandatory to integrate clinical, radiologic, and pathologic data for optimal diagnostic accuracy. 1, 2

• The MDD categorizes diagnostic confidence into four tiers: confident diagnosis (>90% certainty), provisional diagnosis high confidence (70-90%), provisional diagnosis low confidence (50-70%), and unclassifiable ILD (<50% certainty) 1
• Complex or ambiguous cases should be referred to expert ILD centers 1

Treatment Approach by ILD Subtype

Connective Tissue Disease-Associated ILD (except SSc-ILD)

Mycophenolate is the preferred first-line treatment option for most CTD-ILD patients. 5

• Additional first-line options include azathioprine, rituximab, and cyclophosphamide 5
• For rheumatoid arthritis-ILD with active inflammatory arthritis, rituximab may be chosen, particularly considering potential benefits for death and possibly ILD by reducing disease activity 5
• Short-term glucocorticoids may be considered for CTD-ILD other than SSc-ILD, but long-term use should be avoided and reserved for bridging to another therapy 5

Systemic Sclerosis-Associated ILD (SSc-ILD)

• Strongly recommend against glucocorticoids as first-line treatment in SSc-ILD because of their association with scleroderma renal crisis 5
• First-line options include mycophenolate, azathioprine, rituximab, cyclophosphamide, tocilizumab, and nintedanib 5

Idiopathic Inflammatory Myopathy-ILD (IIM-ILD)

• First-line options include mycophenolate, azathioprine, rituximab, cyclophosphamide, JAK inhibitors, and calcineurin inhibitors 5, 1

Idiopathic Pulmonary Fibrosis (IPF)

Antifibrotic therapy with nintedanib or pirfenidone should be started at the time of diagnosis, as these agents reduce annual FVC decline by approximately 44-57%. 1, 3

• Both nintedanib and pirfenidone have comparable efficacy in slowing disease progression 1
• Triple therapy with prednisone, azathioprine, and N-acetylcysteine is contraindicated in patients with definite IPF diagnosis 1
• Immunosuppressive therapy is not effective for IPF and may be harmful 6

Progressive Fibrosing ILD (PF-ILD)

PF-ILD is defined by at least two of the following within 12 months without alternative explanation: (1) worsening respiratory symptoms, (2) absolute FVC decline >5% predicted OR absolute DLCO decline >10% predicted, (3) radiological progression (increased traction bronchiectasis, new ground-glass opacities, new honeycombing, increased extent/thickness of reticular abnormality). 1, 7

• Antifibrotic therapy with nintedanib or pirfenidone is recommended for PF-ILD regardless of the underlying ILD subtype 1

Medications to Avoid

• Conditionally recommend against leflunomide, methotrexate, TNF inhibitors, and abatacept as first-line ILD treatment options 5
• Some panelists would stop these medications if ILD developed while using them 5
• Conditionally recommend against pirfenidone as first-line treatment for SARD-ILD 5
• Conditionally recommend against adding nintedanib or pirfenidone to mycophenolate in patients receiving mycophenolate without evidence of ILD progression 5

Non-Pharmacologic Interventions

• Structured pulmonary rehabilitation improves six-minute walk distance and health-related quality of life 1, 3
• Supplemental oxygen for patients desaturating <88% during a six-minute walk reduces dyspnea and enhances quality of life 1
• Smoking cessation using combined pharmacotherapy (nicotine replacement, varenicline, or bupropion) and behavioral support is the single most effective intervention to slow ILD progression 1
• Ensure age-appropriate vaccinations (influenza and pneumococcal) to lower the risk of respiratory infections 1
• Remove or remediate identified environmental, occupational, or medication triggers 1

Monitoring and Follow-Up

Serial pulmonary function tests (spirometry and DLCO) should be performed every 3-6 months during the first year after diagnosis, then annually if stable. 1, 2

• A 5% decline in FVC over 12 months is associated with approximately 2-fold increased mortality 2, 3
• Follow-up HRCT is recommended 2-3 years after the baseline scan to assess radiologic progression 1
• In patients with high-risk features (definite fibrosis, subpleural fibrotic pattern, extensive radiographic abnormalities, abnormal PFTs, family history of fibrosis, older age, or smoking history), perform earlier HRCT at 12 months 1, 6
• Regular clinical assessment for symptom progression should be performed 1

Advanced Disease Management

Lung Transplant Referral

Patients with elevated risk of mortality should be referred for lung transplantation at the time of diagnosis. 1

• After lung transplant, patients with ILD have a median survival of 5.2-6.7 years compared to less than 2 years in patients with advanced ILD who do not undergo transplant 3

Acute Exacerbations

• Acute exacerbations of ILD are treated with systemic corticosteroids 1
• Routine invasive mechanical ventilation is not recommended for most patients with respiratory failure due to ILD 1

Pulmonary Hypertension

• In patients with end-stage fibrotic ILD who develop pulmonary hypertension, treatment with inhaled treprostinil improves walking distance and respiratory symptoms 3

Co-Management and Shared Decision-Making

Co-management with pulmonologists is advised for initiation of ILD treatment, particularly to determine the need for treatment in asymptomatic patients with stable and mild ILD. 5

• Because most recommendations are conditional, shared decision-making that accounts for ILD severity, risk factors for progression, other disease manifestations, cost, and toxicity is crucial when choosing a medication 5
• Systematic evaluation and treatment of gastroesophageal reflux disease, obstructive sleep apnea, and lung cancer are recommended as part of ILD management 1

Critical Pitfalls to Avoid

• Do not attribute cough and dyspnea solely to ILD without excluding cardiac disease, asthma, and postnasal drainage 1
• Do not dismiss findings as clinically insignificant in asymptomatic patients, as interstitial lung abnormalities are associated with 66% increased risk of death and progression to ILD occurs in approximately 10% annually 1
• Do not use baseline FVC <80% alone to exclude ILD, as it has only 47.5% sensitivity for detecting ILD 1
• Do not rely on chest radiography alone, as up to 10% of ILD patients have normal chest X-rays 1